A5002943087- COVID-19 Clinical Research Studies
- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Long-Term Effects of COVID-19
- COVID-19 and Mental Health
- Lymphoma Diagnosis and Treatment
- Pharmacological Receptor Mechanisms and Effects
- Chronic Lymphocytic Leukemia Research
- Venous Thromboembolism Diagnosis and Management
- Cancer, Lipids, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Coronary Interventions and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
Hospital Israelita Albert Einstein
2023-2024
Previous Randomised controlled trials (RCT) evaluating chloroquine and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant difference hospitalisation rates. However, low statistical power precluded definitive answers.We conducted a multicenter, double-blind, RCT 56 Brazilian sites. Adults with suspected or confirmed presenting mild moderate symptoms ≤ 07 days prior to enrollment at least one risk factor for clinical deterioration were randomised (1:1) receive...
Dual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single (SAPT) strategy with a potent P2Y
Abstract Background Individuals with severe hypercholesterolemia (SH) are considered at high atherosclerosis risk and should be intensively treated lipid-lowering drugs aiming for an LDL-C reduction of≥50% a goal of <70 mg/dL. Objectives This study aimed to evaluate cholesterol control in individuals SH (LDL-C ≥ 190 mg/dL or 160-189 using drugs) followed health evaluation program. Methods 55,000 were evaluated, which 2,214 (4%) had SH, 1,016 (45.8%) repeated assessments. Achievement...
To evaluate deaths, hospitalizations, and persistence of symptoms in patients with COVID-19 after infection an outpatient setting during the first wave Brazil.
Individuals with severe hypercholesterolemia (SH) are considered at high atherosclerosis risk and should be intensively treated lipid-lowering drugs aiming for an LDL-C reduction of≥50% a goal of <70 mg/dL.